Ironwood - A Brighter Year Ahead in 2026 (BUY, TP $15 [17], 10pgs)
For access to the full note please contact Naresh Chouhan ( ).Ironwood Pharmaceuticals is a gastrointestinal (GI), healthcare company focusing on developing the treatment of GI diseases. The company's commercial product, LINZESS? (linaclotide), a guanylate cyclase type C agonists, is indicated for adult men and women suffering from irritable bowel syndrome with constipation, or chronic idiopathic constipation. In addition, the company is developing MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients with abdominal pain associated with certain GI diseases. The company is also developing IW-3718, a gastric retentive formulation of a bile acid sequestrant for the potential treatment of refractory gastroesophageal reflux disease.
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.